Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by RepliCel Life Sciences, Inc.

RepliCel’s Manufacturing Inspected by Japan’s PMDA
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces Material Patent Milestones
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Closed Final Tranche of Strategic Investment Commitment
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Terminates License Agreement with Shiseido
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces Dermal Injector Update
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Economy
Tickers REPCF TSX-V:RP
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Adds Independent Director
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Artificial Intelligence
Tickers REPCF TSX-V:RP
RepliCel Launches Testing of Dermal Injector Units
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Announces Record Year in Patents Granted
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Tickers REPCF TSX-V:RP
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
RepliCel Closes Second Tranche of Strategic Investment Commitment
From RepliCel Life Sciences, Inc.
Via AccessWire
Tickers REPCF TSX-V:RP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.